Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 6c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q3 EPS of ($0.39), $0.06 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $14.7 million versus the consensus estimate of $13.88 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2021 revenue of $40-50 million, versus the consensus of $45.6 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
• Science Applications Int'l (SAIC) Tops Q2 EPS by 70c
• Humana reaffirms 2026 earnings guidance ahead of investor meetings